Document is current
Any future updates will be listed below
-
Authors
Chen, Yijun https://orcid.org/0009-0001-4579-4057
Zeng, Xuemei
Olvera-Rojas, Marcos
Sewell, Kelsey R.
Sehrawat, Anuradha
Gu, Jeremy
Triviño-Ibañez, Eva María
Solis-Urra, Patricio
Gómez- Río, Manuel
Oberlin, Lauren E. https://orcid.org/0000-0001-9553-8070
Kramer, Arthur F.
Hillman, Charles H. https://orcid.org/0000-0002-3722-5612
Burns, Jeffrey M. https://orcid.org/0000-0001-7609-8954
Marsland, Anna L.
Kang, Chaeryon
McAuley, Edward
Ikonomovic, Milos D.
Pascoal, Tharick A. https://orcid.org/0000-0001-9057-8014
Villemagne, Victor L.
Lopez, Oscar L. https://orcid.org/0000-0002-8546-8256
Cohen, Ann D.
Esteban-Cornejo, Irene https://orcid.org/0000-0002-0027-1770
Yates, Nathan A.
Erickson, Kirk I.
Karikari, Thomas K. https://orcid.org/0000-0003-1422-4358
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 AG066468)
U.S. Department of Health & Human Services | National Institutes of Health (P01 AG025204)
U.S. Department of Health & Human Services | National Institutes of Health (R01 AG083874)
- License Information
-
More Information
Article History
Received: 20 August 2024
Accepted: 5 January 2026
First Online: 22 January 2026
Competing interests
: Y.C., X.Z., N.A.Y., and T.K.K. are named inventors on US and worldwide patents filed by the University of Pittsburgh on the streamlined plasma Aβ method described in this manuscript. Disclosure title: “Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer’s Disease;” US Application No.: 63/672,952; PCT Serial No.: PCT/IB2025/057270; Current stage: International search report and written opinion of the international searching authority. The specific aspects of the manuscript covered in the patent application include the streamlined plasma Aβ method and its improved clinical performance. TKK has served as an adhoc consultant and/or advisory board member for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., Alzheon, Siemens Healthineers and Neurogen Biomarking LLC., outside the submitted work. T.K.K. is an inventor on patents and provisional patents regarding biofluid biomarker methods, targets and reagents/compositions, that may generate income for the institution and/or self should they be licensed and/or transferred to another organization. T.K.K. has received royalties from Bioventix for the transfer of specific antibodies and blood biomarker assays to third-party organizations. The remaining authors declare no competing interests.
